Tirzepatide × Body weight

Study 1 · Included

Switching to tirzepatide improves glycemic control and weight in type 2 diabetes

Rct

Comparison

Participants continued with and escalated to dulaglutide. · Participants switched to tirzepatide with escalation.

Duration / follow-up

40 weeks

Study 2 · Included

Tirzepatide improves cardiometabolic health in obesity.

Rct

Comparison

Participants treated with tirzepatide for weight management. · Participants receiving standard care for obesity management.

Duration / follow-up

88 weeks

Study 3 · Included

Tirzepatide improves glycaemic control and weight in type 2 diabetes

Rct

Comparison

Participants receiving tirzepatide 5 mg. · Participants receiving tirzepatide 10 mg. · Participants receiving tirzepatide 15 mg. · Participants receiving insulin glargine.

Duration / follow-up

104 weeks

Study 4 · Included

Tirzepatide improves glycemic control and weight loss in type 2 diabetes

Rct

Comparison

Patients receiving tirzepatide 5 mg for type 2 diabetes management. · Patients receiving tirzepatide 10 mg for type 2 diabetes management. · Patients receiving tirzepatide 15 mg for type 2 diabetes management. · Patients receiving insulin glargine as standard care for type 2 diabetes management.

Duration / follow-up

40 weeks

Study 5 · Included

Tirzepatide improves glycemic control and weight loss sustainability in type 2 diabetes

Rct

Comparison

Participants received tirzepatide administered once weekly. · Participants received treat to target insulin glargine.

Duration / follow-up

208 weeks

Study 6 · Included

Tirzepatide improves glycemic control in early-onset type 2 diabetes

Rct

Comparison

Participants received once weekly tirzepatide treatment. · Participants received either semaglutide, insulin degludec, or placebo.

Duration / follow-up

4 weeks

Study 7 · Included

Tirzepatide improves HbA1c and body weight in Korean adults with T2D

Rct

Comparison

Participants receiving tirzepatide 5 mg via subcutaneous injection. · Participants receiving tirzepatide 10 mg via subcutaneous injection. · Participants receiving tirzepatide 15 mg via subcutaneous injection. · Participants receiving once daily basal insulin.

Duration / follow-up

56 weeks

Study 8 · Included

Tirzepatide improves MASH resolution and fibrosis in diabetes patients

Rct

Comparison

Participants received tirzepatide 5 mg once weekly. · Participants received tirzepatide 10 mg once weekly. · Participants received tirzepatide 15 mg once weekly. · Participants received placebo once weekly.

Duration / follow-up

52 weeks

Study 9 · Included

Tirzepatide improves weight loss in adults with type 2 diabetes

Rct

Comparison

Participants receiving once weekly tirzepatide treatment for type 2 diabetes. · Participants receiving placebo treatment.

Duration / follow-up

40 weeks

Study 10 · Limited

Tirzepatide improves weight loss in type 1 diabetes and obesity

Comparison

Participants received once weekly tirzepatide injections. · Participants received identical appearing placebo injections.

Duration / follow-up

12 weeks

Study 11 · Included

Tirzepatide shows greater HbA1c and weight reduction than Semaglutide

Rct

Comparison

Participants received 5 mg of Tirzepatide. · Participants received 10 mg of Tirzepatide. · Participants received 15 mg of Tirzepatide. · Participants received 1 mg of Semaglutide.

Duration / follow-up

40 weeks